Aktienanalyse zu Evogene Ltd (EVGN)EVGNEvogene Ltd

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It operates in the Healthcare sector.

Evogene Ltd is not a good buy right now due to significant financial losses and poor performance metrics. The current price is $0.2819, with a 52-week high of $1.28, indicating a substantial decline of 76.21% over the past year. Additionally, the RSI is extremely low at 8.602, suggesting oversold conditions but also a lack of buying momentum. The company reported a net loss of $1.8 million in Q2 2026, which is a 62% improvement year-over-year, but still reflects ongoing financial struggles. The main risk is the proxy fight with shareholders, which could further destabilize the company's management and strategy.

2 analysts cover EVGN: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 2.50.